Medicenna Therapeutics Stock Quote MDNA - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.05

Bid

2.03

Ask

2.05

Volume

10,700

2.05 Day's Range 2.09

0.215 52 Week Range 2.98

Market Cap

142.756M

Previous Close

2.08

Open

2.09

Last Trade

1500

2.05

Last Trade Time

12:16:00

Financial Volume

VWAP

Average Volume (3m)

67,282

Shares Outstanding

69,637,000

Dividend Yield

PE Ratio

-5.61

Earnings Per Share (EPS)

-0.37

Revenue

Net Profit

-25.47M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.medicenna.com

Headquarters

Toronto, Ontario, Can

Founded

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $2.08. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.215 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares outstanding. The market capitalization of Medicenna Therapeutics is $144.84 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -5.61.

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...

Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on...

Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy

Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target...

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity...

Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®...

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping...

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.01	-0.485436893204	2.06	2.13	1.91	74317	2.03517712	CS
4	-0.06	-2.84360189573	2.11	2.62	1.91	61307	2.18857372	CS
12	0.08	4.06091370558	1.97	2.62	1.77	67282	2.11645137	CS
26	0.67	48.5507246377	1.38	2.98	1.38	121718	2.10252883	CS
52	1.67	439.473684211	0.38	2.98	0.215	103025	1.53264743	CS
156	-1.12	-35.3312302839	3.17	3.67	0.215	62245	1.50546393	CS
260	0.6	41.3793103448	1.45	7.25	0.215	74660	2.72951241	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VRTSVertiqal Studios Corporation	$ 0.015 (50.00%)	10k
CRWNCrown Capital Partners Inc	$ 1.32 (23.36%)	210
BABYElse Nutrition Holdings Inc	$ 0.035 (16.67%)	222k
SAMStarcore International Mines Ltd	$ 0.125 (13.64%)	19.6k
NVONovo Resources Corp	$ 0.09 (12.50%)	80.31k
ASNDAscendant Resources Inc	$ 0.035 (-22.22%)	1,000
AMMAlmaden Minerals Ltd New	$ 0.065 (-18.75%)	12.81k
CNTCentury Global Commodities Corporation	$ 0.025 (-16.67%)	37.75k
FFFirst Mining Gold Corp	$ 0.135 (-12.90%)	5.93M
XLYAuxly Cannabis Group Inc	$ 0.035 (-12.50%)	110.91k
TRPTC Energy Corporation	$ 61.97 (1.54%)	15.02M
CVECenovus Energy Inc	$ 23.28 (-0.30%)	13.15M
ATHAthabasca Oil Corporation	$ 5.29 (-0.38%)	10.58M
LUNLundin Mining Corporation	$ 13.04 (-2.54%)	10.05M
VRNVeren Inc	$ 8.75 (-0.46%)	9.57M